At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 221 enrolled
Drug / intervention
cangrelor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry
In Brief
A Phase 2 clinical trial evaluating cangrelor and Placebo for Acute Coronary Syndrome (ACS). Completed, enrolled 221 participants across 1 site.
Detailed Summary
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome (ACS)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedOct 2008
Primary CompletionJun 2011
Study CompletionJul 2011
TodayJul 2026
First PostedOct 7, 2008
Enrollment StartOct 1, 2008
Primary CompletionJun 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.7 years ago
Interventions
cangrelordrug
Placeboother
Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.